Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.62 |
| ▸ | PPARD | Q03181 | 2/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422442 | 0.94 | ALOX15 (0.76) | ALOX15ALDH1A1SMN1; SMN2FFAR1PPARD | |
| SCHEMBL339492 | 0.93 | ALOX15 (0.81) | ALOX15ALDH1A1SMN1; SMN2FFAR1PPARD | |
| SCHEMBL4820127 | 0.92 | ALOX15 (0.61) | ALOX15ALDH1A1SMN1; SMN2FFAR1PPARD | |
| SCHEMBL4011865 | 0.90 | MAP4K4 (0.65) | ALOX15ALDH1A1SMN1; SMN2FFAR1PPARD | |
| SCHEMBL421532 | 0.90 | L3MBTL1 (0.59) | ALOX15ALDH1A1SMN1; SMN2FFAR1MAPT | |
| SCHEMBL12646485 | 0.88 | ALOX15 (0.57) | ALOX15ALDH1A1SMN1; SMN2FFAR1PPARD | |
| SCHEMBL23512464 | 0.87 | ALOX15 (0.55) | ALOX15ALDH1A1SMN1; SMN2FFAR1PPARD | |
| SCHEMBL13616217 | 0.87 | PPARD (0.67) | ALOX15ALDH1A1SMN1; SMN2FFAR1PPARD | |
| SCHEMBL4284626 | 0.87 | MMP2 (0.71) | ALOX15FFAR1MAPT | |
| SCHEMBL11552274 | 0.86 | ALOX15 (0.71) | ALOX15ALDH1A1SMN1; SMN2FFAR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3187532-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | Sumitomo Rubber Industries, Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9409951-B2 | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | BRACCO IMAGING S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| EP-1853605-B1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING SPA (IT) | 2014-09-10 | — | — | EP | disclosed |
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
| US-8636977-B2 | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | BRACCO IMAGING S.P.A. (IT) | 2014-01-28 | — | — | US | disclosed |
| US-7666979-B2 | polyvalent targeting ligands that bind to cells used for diagnosis of diseases sensitivity to angiogenesis factor | BRACCO INTERNATIONAL B.V. (NL) | 2010-02-23 | — | — | US | disclosed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
| EP-1853605-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Bracco Imaging, S.P.A. (IT) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | disclosed |
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | BRACCO SUISSE SA (CH) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147555-A1 | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same | LDHB, FPGS, MTHFD2 | ALOX15 1946/4885ALDH1A1 1199/4885SMN1; SMN2 2575/4885 |
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | ITGA2B, ITGB2, ITGB1 | ALOX15 4513/4885ALDH1A1 3450/4885SMN1; SMN2 3277/4885 |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | ITGA2B, ITGB2, ITGB1 | ALOX15 4513/4885ALDH1A1 3450/4885SMN1; SMN2 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.